annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 35E Capturing breast cancer patients’ experience beyond disease progression:
Implementation of a patient-reported outcome (PRO) substudy in the VIRGO
Metastatic Breast Cancer Observational Cohort study. (Abstract #6138)
P. A. Kaufman, N. A. Dreyer, M. Mayer, J. A. Sloan, C. Chung, A. Sing, Y. Yim,
E. Yu, S. D. Mathias, C. S. Cleeland
Brd. 35F Retrospective application of Nottingham Prognostic Index (NPI) and
Adjuvant! Online tool in newly diagnosed patients with early breast cancer in
mid-western Ireland. (Abstract #6139)
K. I. Quintyne, B. Woulfe, R. K. Gupta
Brd. 35G Cost and outcome of vascular resections during pancreaticoduodenectomy.
(Abstract #6140)
G. Bullock, M. J. Ott, T. Belnap, J. R. Whisenant
Brd. 35H Technologic advancements and error rates in radiation therapy (RT) delivery.
(Abstract #6141)
D. N. Margalit, K. Heckman, Y. Chen, P. J. Catalano, T. Vivenzio, K. Nissen,
P. Mauch, A. K. Ng
Brd. 36A Impact of CPOE on workflow and direct patient care time in an inpatient
hematology/oncology service. (Abstract #6142)
D. A. Hanauer, K. Zheng, S. W. Choi, R. Beasley, J. Schumacher, M. Duck,
D. W. Blayney
Brd. 36B Novel uses of coded data in clinical trials. (Abstract #6143)
A. Daunton, D. Liu, S. I. Collins, A. Pope, D. Barton, D. Ray, N. D. James
Brd. 36C Factors influencing the career decisions of United States hematology
oncology fellows training at NCI- and NCCN-designated cancer centers.
(Abstract #6144)
L. Horn, E. Koehler, Y. Shyr, J. Gilbert, D. H. Johnson
Brd. 36D Continuity of care for cancer patients at the end of life (EoL). (Abstract #6145)
R. Bascioni, B. Esperide, D. Iacopini, F. Basirat, F. Rastelli, L. Acito, R. Bisonni,
L. Giustini, F. Giorgi
Brd. 36E Care delivery barriers to personalized medicine in breast cancer.
(Abstract #6146)
J. C. Schink, C. B. Weldon, J. R. Trosman, A. B. Benson, A. I. Löffler,
W. J. Gradishar
Brd. 36F Hepatitis B screening prior to chemotherapy: A survey of practitioners’
knowledge, beliefs, and screening practices. (Abstract #6147)
R. Lee, C. M. Bell, L. K. Hicks
Brd. 36G The role of patient advocates in clinical trials: Perspectives from
investigators and advocates in the Cancer and Leukemia Group B (CALGB).
(Abstract #6148)
M. L. Katz, L. Archer, J. M. Peppercorn, S. Kereakoglow, D. Collyar, H. J. Burstein,
R. L. Schilsky, A. H. Partridge
Brd. 36H Prescribing and safety issues of oral molecular therapies and
chemotherapies in Australian haematology oncology practice. (Abstract
#6149)
M. J. Dooley, M. A. Larizza, S. G. Poole, C. Carrington
Brd. 37A Comparison of hospital costs versus DRG reimbursement for treatment of
febrile neutropenia during adjuvant CTX for primary breast cancer.
(Abstract #6150)
S. C. Mayer, A. Ihbe-Heffinger, B. Paessens, U. R. Schwarz-Boeger, J. Ettl,
S. Paepke, R. Bernard, N. Harbeck, M. Kiechle, V. R. Jacobs
Brd. 37B Development and testing of multiple versions of a radiation oncology
treatment planning workflow application in the era of HIPAA.
(Abstract #6151)
J. B. Fiveash, J. Howerton, M. Hyatt, K. Sinclair, O. L. Burnett, R. A. Popple,
B. Graham
376